Simple Summary Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro. Abstract Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
【저자키워드】 convalescent plasma, SARS-CoV-2, IgG, coronavirus, antibody, ELISA, 【초록키워드】 COVID-19, coronavirus disease, passive immunization, Efficacy, SARS-COV-2 infection, disease severity, Infection, Gender, in vitro, virus, immunization, serum, Neutralizing activity, Cohort, Health, IgG antibody, Hyperimmune plasma, RBD, therapeutic, Patient, death, plasma, spike receptor-binding domain, large cohort, Neutralizing, donors, convalescent, Quantitative, predict, convalescent patient, Donor, B-cell, Concentration, Anti-RBD IgG, plasma concentration, help, RBD IgG, ELISA test, simple, responses, Prevent, independent, detection system, significantly, diagnosed, correlated, induce, COVID-19 convalescent patient, patients with COVID-19, remains uncertain, treatment for COVID-19, 【제목키워드】 activity, the Spike, Determination,